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The use of antibiotics as pre- or post-exposure prophylaxis for STI prevention (STI prophylaxis) is not 
currently recommended in the UK, but there is evidence that self-prescribing occurs among those at 
greatest risk. We present the prevalence and factors associated with STI prophylaxis among a 
community sample of HIV PrEP users. 
 
Methods 
The 2019 online PrEP User Survey ran between 17 May – 1 July. Eligible participants included UK 
residents reporting HIV PrEP use or having tried to obtain HIV PrEP, since January 2017. STI prophylaxis 
use was defined as reporting buying antibiotics to prevent STIs, either privately or through the internet; 
this question was only asked to HIV PrEP users. Factors associated with STI prophylaxis use were 
assessed using univariable and multivariable logistic regression. 
 
Results 
Overall, 9% (167/1,856) of HIV PrEP users reported STI prophylaxis use; 97% were gay or bisexual men, 
84% reported white ethnicity, 55% resided in London and 69% were aged ≥35 years. Factors associated 
with STI prophylaxis included: reporting ≥5 compared to 1-4 condomless sex partners in the past 6 
months (12% vs. 5.6%, aOR=1.80; 95%CI=1.22-2.64), reporting chemsex drug use compared to no 
sexualised drug use in the past 12 months (13% vs. 6.0%, aOR=1.88; 95%CI=1.20-2.93) and reporting an 
STI diagnosis in the past 12 months (12% vs. 6.6%, aOR=1.54; 95%CI=1.08-2.18). Variables not significant 
in multivariable analyses included: ethnicity, age, residence and HIV PrEP sourcing. 
 
Conclusions 
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Approximately one in ten HIV PrEP users from this community sample reported self-prescribed STI 
prophylaxis. STI prophylaxis was associated with sexual behaviour known to facilitate STI transmission 
and with a history of recent STIs acquisition. Given the potential risk of antimicrobial resistance, sexual 
health clinicians should consider asking attendees, especially HIV PrEP users, about the use of antibiotics 
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There is growing concern over the burden of bacterial sexually transmitted infections (STIs) reported 
among individuals using HIV Pre-Exposure Prophylaxis (HIV PrEP) to prevent HIV (1-3). A meta-analysis of 
STI prevalence and incidence among individuals using HIV PrEP estimated a pooled STI prevalence of 
24% among individuals initiating HIV PrEP and a pooled STI incidence of 72.2 per 100 person-years 
during persistent HIV PrEP use(3).  
 
In the same way that antiretroviral therapy is used to prevent HIV infection in the forms of PrEP and 
post-exposure prophylaxis (PEP), there is evidence that antibiotics for STI treatment could be used to 
prevent STIs. Doxycycline is a tetracycline antibiotic, which is commonly used as primary prevention 
(pre- and post-exposure prophylaxis) for several infectious diseases(4) and bacterial STIs treatment, but 
more recently has been assessed by studies as a preventative intervention for STIs(5). A sub-study of the 
ANRS-IPERGAY trial in France among 232 high risk men who have sex with men (MSM) using HIV PrEP, 
showed that Doxycycline post-exposure prophylaxis (Doxy-PEP) following condomless sex, was effective 
in reducing incidence of a first episode of chlamydia and syphilis but not gonorrhoea(6). Use of 
Doxycycline as pre-exposure prophylaxis (Doxy-PrEP) significantly reduced the number of gonorrhoea, 
chlamydia and syphilis diagnoses within the intervention arm among MSM with HIV in a small 
randomised controlled trial in the United States(7). However, this study is limited by the small sample 
size (n=30) and because participants received financial incentives for remaining STI negative. 
 
A key concern about STI prophylaxis use is that any potential reduction in an individual’s acquisition of 
specific STIs may be outweighed by harms associated with widespread, unprescribed and unmonitored 
use of tetracycline antibiotics. In 2017, Public Health England (PHE) and The British Association for 
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Sexual Health and HIV (BASHH) advised against Doxy-PEP use due to the risk of increasing antimicrobial 
resistance (AMR) in STI pathogens and other bacterial species(8). Isolates collected through PHE’s 
Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in 2018 showed 53% were 
resistant to tetracycline(9), therefore Doxy-PEP/PrEP is unlikely to be effective at preventing  Neisseria 
gonorrhoeae infection. Treatment success rates with tetracyclines for Chlamydia trachomatis and 
Treponema pallidum remain high with limited evidence for tetracycline resistance (10). Although 
tetracyclines have limited efficacy in clearing Mycoplasma genitalium they are used in treatment 
regimens and AMR is a major concern in this organism(11).  Additionally, unanswered questions remain 
surrounding the efficacy, safety, appropriate dose, target population, acceptability, cost-effectiveness 
and risk-benefit of Doxy-PEP/PrEP in the general population(5). 
 
In the UK, patients can access antibiotics through prescription from healthcare professionals (HCPs), 
although more recently online pharmacies are selling generic Doxycycline directly to the public, without 
prescription or oversight from HCPs. Despite uncertainties over effectiveness and safety and lack of 
endorsement by professional organisations, emerging evidence suggests key populations are already 
self-prescribing STI prophylaxis(12-14). Little is known about who are using it, how these individuals 
become aware of the availability of antibiotics privately without prescription, and motivations for use. 
Potential reasons for STI prophylaxis use could be increased awareness and community discussions 
about STI burden in specific risk groups and the ease of informal access online. Private HIV PrEP users 
could be alerted to online pharmacies selling antibiotics if purchasing HIV PrEP through the same 
internet retailer.   
 
The PrEP User Survey aims to capture experiences of using and accessing HIV PrEP among people living 
in the UK. We used 2019 survey data to estimate the prevalence and predictors of STI prophylaxis use 
among UK HIV PrEP users, to add to our knowledge on STI prophylaxis and inform the public health 
response to STI and AMR control. 
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The PrEP User Survey is an online, cross-sectional survey that was first conducted in 2017, led by 
PrEPster and iwantPrEPnow (community-based organisations educating about PrEP and PrEP access in 
the UK) to inform their PrEP activism activities. In 2018 and 2019, PHE joined the collaboration. The 
survey was approved by the PHE Research Ethics and Governance Group (reference number NR0118) in 
2018. Participation was voluntary and the information provided and experience of completing the 
anonymous, online survey ensured that consent was implied. The survey aims to characterise and 
capture experiences of HIV PrEP users, explore barriers to use and to estimate the current number of UK 
users, irrespective of the source of PrEP (publicly-funded programmes or privately purchased)(15).  
 
This analysis used data exclusively from the 2019 survey round, following previous surveys in 2017 and 
2018. The survey recruits participants from the iwantPrEPnow mailing list, generated from individuals 
requesting updates on PrEP availability via the iwantPrEPnow website, and the PrEPster mailing list 
generated from individuals attending PrEPster events and given permission to be contacted about 
future events and activity, including research participation requests. The 2019 survey additionally 
recruited participants through social media (Facebook, Instagram, Twitter) and Grindr (a geosocial 
networking application); participants were eligible if they were UK residents and reported HIV PrEP use 
or unsuccessfully trying to obtain HIV PrEP, since January 2017. Recruitment for 2019 took place from 17 
May to 1 July; data were collected on participant demographics, HIV PrEP use and access, sexual 
behaviour, HIV and STI testing practices and STI diagnoses.    
 
This analysis only includes individuals from the 2019 survey round who reported HIV PrEP use since 
January 2017. STI prophylaxis use was defined by an affirmative response to the question introduced in 
2019: “Do you buy antibiotics to prevent STI infections, either privately or through the internet?”.  The 
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term “antibiotics” was used instead of Doxycycline, as previous studies suggest individuals also purchase 
other antibiotics for STI prophylaxis(12,14). Only individuals reporting HIV PrEP use in the 2019 survey 
were asked about STI Prophylaxis use, hence our analyses do not include those who tried but were 
unable to obtain HIV PrEP.   
 
Factors associated with STI prophylaxis use were identified using logistic regression. Variables were 
considered for inclusion in multivariable analyses if they were of interest (i.e. deemed important 
predictors for STI prophylaxis use) and/or significant at p<0.100 in univariable analyses. A backwards 
stepwise approach was used for the final multivariable model, with variables retained if significant at 




Sample characteristics of HIV PrEP users (Supplementary Table 1) 
Overall, 2,389 participants submitted responses between 17 May and 1 July 2019; 1,856 (78%) 
individuals reported HIV PrEP use since January 2017. A description of these participants is detailed in 
Supplementary Table 1. The majority identified as white gay or bisexual men, aged ≥35 years, living in 
England.  
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STI prophylaxis users vs. non-STI prophylaxis users (Supplementary Table 2) 
Of the 1,856 HIV PrEP users, 167 (9%) reported STI prophylaxis (1,681 reported no STI prophylaxis use 
and eight did not answer). Of the 167 STI prophylaxis users, the majority (97%, 162/167) reported male 
gender and identified as gay or bisexual, 84%(141/167) reported white ethnicity, 69% (115/167) were 
aged ≥35 years. Similar gender, sexual orientation ethnicity and age breakdowns were reported among 
non-STI prophylaxis users. Of participants who identified with a gender different to that assigned at 
birth (n=23), none reported STI prophylaxis. 
 
Most STI prophylaxis users (61%, 101/167), were recruited through IwantPrEPnow and PrEPster mailing 
lists, with the remaining recruited through Grindr (17%, 29/167), social media (15%, 25/167) and other 
means (7%, 11/167). Smaller proportions of non-STI prophylaxis users were recruited through mailing 
lists (52%, 878/1,681) with a larger proportion recruited through Grindr (23%, 387/1,681) (p=0.155). Just 
over half of STI prophylaxis users reported living in London (55%, 91/167), 41% (69/167) in England 
outside London and 4.2% (7/167) in Scotland, Wales and Northern Ireland. Smaller proportions of non-
STI prophylaxis users lived in London (48%, 798/1,681, p=0.375). 
 
Just over half of STI prophylaxis users last sourced HIV PrEP through the Impact Trial in England(16) or 
another publicly funded programme in devolved administrations (58%, 97/167) and 42% (70/167) 
through online purchase or other private sources. Similar HIV PrEP sources were reported among non-
STI prophylaxis users. Just over a quarter (26%, 44/167) of STI prophylaxis users reported sharing or 
selling HIV PrEP compared to 15% (253/1,681) among non-STI prophylaxis users (p<0.001). Similar 
proportions reported taking HIV PrEP daily in both STI prophylaxis and non-STI prophylaxis groups (75% 
and 75% respectively). 
 
The majority of STI prophylaxis users and non-STI prophylaxis users reported condomless sex in the past 
six months (96% and 95% respectively); however, a larger proportion of STI prophylaxis users reported 
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≥5 condomless sex partners (72% vs. 41% respectively, p<0.001). Three-quarters (75%, 125/167) 
reported using drugs just before or during sex in the past 12 months compared to 61% (1,027/1,681) 
among non-STI prophylaxis users (p<0.001). A third (33%, 55/167) reported using ≥1 chemsex-associated 
drugs compared to a fifth (22%, 364/1,681) among non-STI prophylaxis users (p<0.001). Injecting drug 
use in the last 12 months was reported among 9.0% and 3.9% of STI prophylaxis users and non-STI 
prophylaxis users respectively (p<0.001).  
 
A slightly larger proportion of STI prophylaxis users (81%, 135/167) reported ≥3 HIV tests in the last year 
compared to non-STI prophylaxis users (77%, 1,286/1,681, p=0.031) and similar proportions reported 
having their last HIV test at a sexual health clinic (SHC) (86% and 87% respectively). Just under two-
thirds reported having ≥3 STI tests in the last year in both STI prophylaxis users and non-users (65% and 
64% respectively), with the majority having their last test STI test at a SHC (89% and 90% respectively). A 
larger proportion of STI prophylaxis users (63%, 105/167) reported an STI diagnosis in the last 12 months 
compared to non-STI prophylaxis users (48%, 805/1,681, p<0.001). Among those reporting STI 
diagnoses, a higher proportion reported a chlamydia diagnosis among STI prophylaxis users compared to 
non-STI prophylaxis users (66% vs. 60.4%, p<0.001) and a lower proportion reported a gonorrhoea 
diagnosis among STI prophylaxis users (57% vs. 67%, p=0.279). 
 
Factors associated with STI prophylaxis use (Supplementary Table 2) 
In univariable analyses, higher odds of STI prophylaxis use were observed among HIV PrEP users 
reporting the following; being aged 35-44 compared to <35 years, reporting ≥5 compared to between 1-
4 condomless sex partners in the last six months, chemsex and injecting drug use compared to no drug 
use just before or after sex in the last 12 months and an STI diagnosis in the last 12 months. Lower odds 
of STI prophylaxis use were observed among HIV PrEP users reporting <3 compared to no HIV tests in 
the last 12 months. These variables were included in the multivariable analyses. Gender, sexual 
orientation, method of survey recruitment, HIV PrEP source, PrEP dosing regimen, transactional sex, SHC 
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attendance, setting of last HIV or STI test, number of STI tests in the last year, STI diagnoses other than 
Chlamydia and sex life satisfaction were not significantly associated with STI Prophylaxis use. Sharing or 
selling HIV PrEP and being diagnosed with Chlamydia were significantly associated with STI Prophylaxis 
use in univariable analyses but were not included in multivariable analyses as they were not apriori 
variables of interest. Residence and ethnicity, although not significantly associated with the outcome in 
the univariable analyses, were included as apriori variables of interest. Injecting drug use was not 
retained in the final multivariable model due to collinearity with chemsex. Residence, ethnicity, number 
of HIV tests in the last 12 months and age were also not retained as they significantly reduced the 
goodness of fit of the model at p≥0.050 using the likelihood-ratio test. 
 
In the final multivariable model , statistically significant associations were observed between reporting 
STI prophylaxis use and: reporting ≥5 compared to 1-4 condomless sex partners in the past 6 months 
(aOR=1.80 [95% CI: 1.22 – 2.64], p=0.003), using ≥1 chemsex-associated drugs just before or during sex 
compared to no sexualised drug use in the past 12 months (aOR=1.88 [95% CI: 1.20 – 2.93], p=0.006) 





To our knowledge, this is the largest community-based study exploring STI prophylaxis use among HIV 
PrEP users. Our findings show 9.0% (167/1,856) of individuals among our cohort of high-risk HIV PrEP 
users in 2019 reported privately purchasing antibiotics to prevent STIs. Most notably, we also found STI 
prophylaxis use to be geographically widespread in the UK and associated with higher risk for HIV/STIs; 
multiple condomless sex partners, chemsex and STI diagnoses.  
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This analysis has various strengths. In addition to the relatively large sample size compared to other STI 
prophylaxis research, our PrEP User Survey had wide geographical coverage and is an annual, 
established survey. Community sampling methods allowed access to diverse HIV PrEP user groups across 
the UK, not limited to SHC attendees. The survey was piloted using small focus groups and data were 
anonymously self-reported, reducing social desirability bias. We collected extensive information on 
sexual behaviour and sexual health, allowing us to explore a variety of risk factors and build a 
comprehensive profile of survey participants, taking our knowledge further than previous surveys 
examining predictors of STI prophylaxis(12-14). 
 
Our survey also has limitations. As we recruited individuals online, and predominantly MSM, there is 
potential for participation and self-selection bias, meaning our sample and findings may not be 
representative of all UK HIV PrEP users. Our recruitment included promotion through PrEPster and 
iwantPrEPnow mailing lists, potentially skewing our sample towards higher-risk MSM seeking 
information on HIV PrEP. Our survey was only conducted in English and therefore not representative of 
non-English speaking HIV PrEP users. Cognitive testing of the STI prophylaxis use question was not 
performed and may have led to misinterpretation. The question also refers to buying antibiotics and 
may not have captured STI prophylaxis users accessing antibiotics through other informal channels. We 
also did not capture other key variables related to STI prophylaxis such as specific antibiotics used, 
access routes, how they were used (e.g. as pre- or post-exposure prophylaxis, daily or on-demand 
dosing), how often and for how long. These data could help us understand the likely effectiveness of 
individual STI prophylaxis practices and methods of use. As we restricted our survey question on STI 
prophylaxis to HIV PrEP users, our findings are not generalisable to other populations, including non-HIV 
PrEP users and MSM living with diagnosed HIV.  
 
Our 9% prevalence of STI prophylaxis use is similar to smaller studies quantifying STI prophylaxis use in 
SHC attendees attending HIV PrEP follow-up. In 2018, 9.9% (n=105) of 1,065 MSM HIV PrEP users 
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attending a SHC in Melbourne, Australia, reported Doxycycline prophylaxis in the last month(13). Also in 
2018, 8% (n=46) of 106 MSM HIV PrEP users attending a SHC in London, UK, reported taking antibiotics 
to prevent STIs(12). A study among 321 MSM recruited through eight STI clinics in the Netherlands in 
2018 observed a smaller prevalence estimate (2.2%, n=7) reporting STI prophylaxis, however this study 
included MSM not taking HIV PrEP(14). These three studies provide useful references for STI prophylaxis 
prevalence and risk factors, but cannot be directly compared for various reasons. Firstly, they were 
conducted among SHC attendees, and may have different demographics, risk behaviours, risk 
perception and how these are reported, compared to our community sample. The Dutch study did not 
restrict to HIV PrEP users, therefore risk profiles in their sample will differ. Questions on STI prophylaxis 
were phrased differently between studies, likely leading to differing interpretations, for example the 
Dutch and London studies asked about antibiotic use as STI prophylaxis, whereas the Melbourne study 
limited to Doxycycline use. Sample sizes were also smaller compared to our survey, potentially 
decreasing the power to detect effects. Our survey is more recent and may reflect changes in 
behaviours, HIV PrEP use, infection epidemiology and STI prophylaxis awareness since the other surveys 
were conducted.  
 
Our research indicates reported STI prophylaxis use is more common among HIV PrEP users at higher 
risk of HIV/STIs, as we observed significant associations with reporting ≥5 condomless sex partners in 
the past 6 months, and chemsex and reported STI diagnoses in the last 12 months. Although not 
retained in the final multivariable model, injecting drug use was associated with STI prophylaxis in our 
univariable analyses, as was observed in the Melbourne study multivariable model(13). These 
associations with higher STI risk behaviours may reflect HIV PrEP users having an increased awareness of 
risk behaviours, assessing their individual heightened risk for STIs, and mitigating against that risk 
through self-prescription of antibiotics. A recent meta-analysis of studies reporting sexual risk outcomes 
in HIV PrEP users found that commencing HIV PrEP led to an increase in anorectal STIs, suggesting HIV 
PrEP use is associated with a decline in condom use for anal sex (17). This altered risk perception and 
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behaviour change may also be mirrored in STI prophylaxis initiation, whereby users engage in increased 
STI risk behaviours due to the perception that antibiotic use has a protective effect on the risk of STI 
acquisition. Additionally, those engaging in higher STI risk behaviours may be less risk averse, and more 
likely to use STI prophylaxis, despite a paucity of evidence supporting its effectiveness and no 
endorsement from professional and public health bodies. 
 
Interestingly, ethnicity, age and residence were not significantly associated with STI prophylaxis in the 
multivariable analysis. This suggests that STI prophylaxis use may be geographically widespread and 
dispersed across age, residence and ethnic groups. We expected private HIV PrEP use to be associated 
with STI prophylaxis, as these individuals are already sourcing HIV PrEP through the internet or other 
informal routes; however no significant association was observed.  
 
Although it appears STI prophylaxis is an emerging phenomenon among higher-risk MSM, there are 
growing concerns over the potential of widespread STI prophylaxis use to select AMR in STIs and other 
bacterial pathogens. Future research quantifying this risk are welcomed. Frequent antimicrobial 
exposure for STI treatment in MSM is thought to facilitate development of resistance in target and non-
target organisms, such as Shigella spp.(18, 19). More evidence is also needed to determine the 
effectiveness of antibiotics as Pre-Exposure STI prophylaxis for individual STI pathogens. As STI 
prophylaxis users in our cohort obtained antibiotics privately, it is likely they were not clinically advised 
on individual need and the appropriate use of these medicines. There are also concerns over drug 
integrity, dosage, storage, transportation and supporting information on safe and correct use by 
suppliers. The UK currently does not recommend the use of antibiotics as STI prophylaxis; hence 
individuals may be reluctant to disclose this to clinicians, hindering provision of appropriate support.  
Routine data collection of STI prophylaxis use among SHC attendees as part of sexual history could 
inform clinical risk assessment and provision of appropriate clinical advice on testing frequency and test 
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of cure, as well as good antimicrobial stewardship. Additionally, awareness and public health education 
on the informal use and abuse of antibiotics, for both patients and providers, would be beneficial. 
 
Our study provides scope for further research. We did not ask which antibiotics participants were using, 
where they were sourced, how they were used, frequency and length of use, adherence and 
motivations for use, which should be explored in future surveys. Subsequent survey rounds could also 
provide insight into trends in STI prophylaxis use and extent of use in other groups, including non-HIV 
PrEP users. Furthermore, larger, more robust studies on the effectiveness of STI prophylaxis on the 
incidence of different STIs, and the long-term impact of frequent antibiotic use on target and non-target 
organisms, are urgently needed.  
 
 
Key Messages (3-4 bullet points max. 25 words each)  
● STI prophylaxis describes the use of antibiotics to prevent STI acquisition, however national 
estimates of its use among HIV PrEP users has not been quantified.  
● Small studies have reported effectiveness of STI prophylaxis in reducing incidence of certain STIs, 
but there are concerns over its potential to contribute to AMR.  
● 9% of HIV PrEP users in the United Kingdom reported STI prophylaxis, purchasing antibiotics to 
prevent STIs, either privately or through the internet 
● STI prophylaxis was associated with reporting ≥5 condomless sex partners (past 6 months), 
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sectional online community survey, May to July 2019, United Kingdom 
Supplementary Table 1: Sample characteristics of participants reporting HIV PrEP use since January 2017 
(n=1,856), 2019 PrEP User Survey 
  
Participants reporting 
HIV-PrEP use since 
January 2017 
(N=1,856) 
Variable Values  n % 
DEMOGRAPHICS 
Gender identity Man (incl. trans man)    1,824  98% 
Other gender          29  2% 
Prefer not to say            3  0% 
Sexual Orientation* Gay man No     134  7% 
Yes  1,722  93% 
Bisexual No  1,732  93% 
Yes     124  7% 
Ethnicity White    1,581  85% 
Asian       113  6% 
Mixed          54  3% 
Black          48  3% 
Other          45  2% 
Prefer not to say          15  1% 
Age 16 - 34       703  38% 
35-44       582  31% 
45+       567  31% 
Prefer not to say            4  0% 
Residence London       892  48% 
Midlands & East of England       207  11% 
North of England       301  16% 
South of England       333  18% 
Scotland          62  3% 
Wales          37  2% 
Northern Ireland          17  1% 
Prefer not to say            7  0% 
Recruitment to survey Mailing list/email       986  53% 
Grindr       417  22% 
Social media       331  18% 
Other       105  6% 
Not Reported          17  1% 
PrEP USE 
Last sourced PrEP from‡ Trial/programme    1,120  60% 
Privately / Other       731  39% 
Not Reported            5  0% 
No    1,555  84% 
Ever shared or sold PrEP intended for 
yourself or bought by yourself 
Yes       298  16% 
Not Reported            3  0% 
Dosing Daily    1,383  75% 
Other       473  25% 
SEXUAL BEHAVIOUR 
Number of condomless vaginal and/or anal 
sex partners in past 6 months 
None          92  5% 
1-4 partners       721  39% 
5 or more partners    1,040  56% 
Not reported            3  0% 
Transactional sex in past 6 months Yes       102  5% 
No    1,746  94% 
Not Reported            8  0% 
Drug use just before or during sex in 
past 12 months - chemsex (4 chems) 
No drug use       671  36% 
Yes - 1 or more of 4 chemsex drugs       419  23% 
Yes - none of 4 chems       739  40% 
Not Reported          27  1% 
Injecting drug use just before or during 
sex in past 12 months  
No drug use       671  36% 
Yes - injecting          80  4% 
Yes - no injecting    1,072  58% 
Not Reported          33  2% 
SEXUAL HEALTH 
Visited sexual health clinic in last year Yes    1,758  95% 
No          98  5% 
Number of HIV tests in the last 12 
months  
0          41  2% 
1-2       378  20% 
3+    1,421  77% 
Not Reported          16  1% 
Setting of last HIV test Sexual health clinic    1,605  86% 
Self-sampling / self-testing service / GP / 
Other       243  13% 
Not Reported            8  0% 
Number of STI tests (excluding HIV) in 
last 12 months 
0       243  13% 
1-2       412  22% 
3+    1,191  64% 
Not Reported          10  1% 
Setting of last STI test Sexual health clinic    1,660  89% 
Self-sampling / self-testing service / GP / 
Other       178  10% 
Not Reported           18  1% 
STI diagnosis in last 12 months Yes       911  49% 
No       935  50% 
Not Reported          10  1% 
STI(s) diagnosed in last 12 months* Gonorrhoea Yes     596  32% 
No  1,260  68% 
Chlamydia Yes     555  30% 
No  1,301  70% 
Syphilis Yes     153  8% 
No  1,703  92% 
Other Yes        58  3% 
No  1,798  97% 
Satisfied with sex life Strongly Agree / Agree    1,276  69% 
Neither disagree or agree       354  19% 
Strongly Disagree / Disagree       226  12% 
*For this question, respondents could pick multiple answers    
‡ PrEP Sourcing:  Trial = PrEP users who last sourced their PrEP either through the Impact trial in England, another trial, or a 
sexual health clinic in Scotland, Wales or Northern Ireland. Private/Other=PrEP users who last sourced PrEP either through 




Supplementary Table 2. Factors associated with reporting STI prophylaxis use among HIV PrEP Users from 2019 PrEP User Survey (N=1,856)     
 Reporting STI prophylaxis use (N=167) 
  Univariable analyses Multivariable analyses 
Variable Values Total n % 
Unadjusted Odds 
Ratio (OR) (95% CI) 




Gender identity Man (incl. trans man)  1,824  165 9.1 1.00    
Other gender   29  1 3.5 0.36 (0.48 - 2.64) 0.314   
Sexual Orientation* Gay man No  134  15 11 1.00    
Yes 1,722  152 8.9 0.77 (0.44 - 1.35) 0.367   
Bisexual No 1,732  152 8.8 1.00    
Yes  124  15 12 1.42 (0.81 - 2.50) 0.221   
Ethnicity° White  1,581  141 9.0 1.00    
BAME (Black, Asian and Minority 
Ethnic groups) /Other ethnic group 
  260  26 10 
1.13 (0.73 - 1.76) 0.576   
Age° 16 - 34   703  52 7.4 1.00    
35-44   582  61 11 1.47 (1.00 - 2.17) 0.050   
≥45   567  54 9.6 1.33 (0.89 - 1.98) 0.159   
Residence° London   892  91 10 1.00    
Midlands & East of England   207  16 7.7 0.73 (0.42 - 1.28) 0.275   
North of England   301  22 7.4 0.70 (0.43 - 1.14) 0.152   
South of England   333  31 9.3 0.90 (0.59 - 1.39) 0.641   
Scotland, Wales, Northern Ireland   116  7 6.0 0.56 (0.25 - 1.25) 0.157   
Recruitment to survey Mailing list/email   986  101 10 1.54 (1.00 - 2.36) 0.050   
Grindr   417  29 7.0 1.00    
Social media   331  25 7.6 1.09 (0.63 - 1.90) 0.760   
Other   105  11 11 1.56 (0.75 - 3.24) 0.231   
PrEP USE 
Last sourced PrEP from‡ Trial/programme  1,120  97 8.7 1.00    
Privately / Other   731  70 9.7 1.12 (0.81 - 1.55) 0.475   
Ever shared or sold PrEP intended for yourself or 
bought by yourself 
No  1,555  123 8.0 1.00    
Yes   298  44 15 2.01 (1.39 - 2.92) <0.001   
Dosing Daily  1,383  125 9.1 1.00    
Other, including event based, 4-6 times 
a week, intermittently, one-off(s)   473  42 8.9 0.98 (0.68 - 1.41) 0.916   
SEXUAL BEHAVIOUR 
Number of condomless vaginal and/or anal sex 
partners in past 6 months 
0   92  7 7.6 1.4 (0.61 - 3.22) 0.429 1.43 (0.58 - 3.50) 0.434 
1-4    721  40 5.6 1.00  1.00  
≥5  1,040  120 12 2.23 (1.54 - 3.24) <0.001 1.80 (1.22 - 2.64) 0.003 
Transactional sex in past 6 months Yes   102  12 12 1.36 (0.73 - 2.54) 0.333   
No  1,746  155 8.9 1.00    
Drug use just before or during sex in past 12 
months / Chemsex (4-chems)† 
No drug use just before or during sex   671  40 6.0 1.00  1.00  
Yes incl. 1 or more of 4 chemsex drugs   419  55 13 2.38 (1.55 - 3.64) <0.001 1.88 (1.20 - 2.93) 0.006 
Yes - but none of 4 chemsex drugs   739  70 9.6 1.66 (1.11 - 2.49) 0.014 1.44 (0.95 - 2.18) 0.082 
Injecting drug use just before or during sex in past 
12 months° 
No drug use just before or during sex   671  40 6.0 1.00    
Injecting drug use   80  15 19 3.63 (1.90 - 6.92) <0.001   
Drug use but no injecting  1,072  106 10 1.79 (1.23 - 2.61) 0.002   
SEXUAL HEALTH 
Visited sexual health clinic in last 12 months Yes  1,758  156 8.9 0.77 (0.40 - 1.48) 0.439   
No   98  11 11 1.00    
Number of HIV tests in the last 12 months° 0   41  7 17 1.00    
1-2   378  24 6.4 0.33 (0.13 - 0.82) 0.017   
≥3  1,421  135 9.5 0.73 (0.09 - 6.02) 0.774   
Setting of last HIV test Sexual health clinic  1,605  143 9.0 1.00    
Self-sampling / self-testing service / GP 
/ Other  243  22 9.1 1.02 (0.64 - 1.63) 0.942   
Number of STI tests (excluding HIV) in last 12 
months 
0   243  19 7.9 1.00    
1-2   412  38 9.2 1.23 (0.62 - 2.45) 0.548   
≥3  1,191  109 9.2 1.18 (0.71 - 1.97) 0.516   
Setting of last STI test Sexual health clinic  1,660  148 9.0 1.00    
Self-sampling / self-testing service / GP 
/ Other   178  18 10 1.14 (0.68 - 1.91) 0.611   
STI diagnosis in last 12 months Yes   911  105 12 1.86 (1.33 - 2.58) <0.001 1.54 (1.08 - 2.18) 0.016 
No   935  61 6.6 1.00  1.00  
STI(s) diagnosed in last 12 months* Gonorrhoea Yes  596  60 10 1.20 (0.86 - 1.67) 0.280   
No 1,260  107 8.5 1.00    
Chlamydia Yes  555  69 12 1.73 (1.25 - 2.40) 0.001   
No 1,301  98 7.6 1.00    
Syphilis Yes  153  19 12 1.48 (0.89 - 2.47) 0.130   
No 1,703  148 8.7 1.00    
Other Yes  58  8 14 1.64 (0.76 - 3.52) 0.204   
No 1,798  159 8.9 1.00    
Satisfied with sex life Strongly Agree / Agree  1,276  120 9.5 1.00    
Neither disagree or agree   354  22 6.2 0.63 (0.40 - 1.01) 0.058   
Strongly Disagree / Disagree   226  25 11 1.19 (0.75 - 1.88) 0.455   
*For this question, respondents could pick multiple answers     
° Ethnicity, age, residence and number of HIV tests in the last 12 months were included in multivariable analysis but not entered into final model as they were not statistically 
significantly associated with outcome using the likelihood-ratio test. Injecting drug use was not entered into final model due to collinearity with chemsex. 
†Chemsex: Defined as reported using one or more of the following four drugs just before or during sex: crystal methamphetamine, gamma-hydroxybutyrate / gamma-butyrolactone 
(GHB/GBL), mephedrone, ketamine 
‡ PrEP Sourcing:  Trial = PrEP users who last sourced their PrEP either through the Impact trial in England, another trial, or a sexual health clinic in Scotland, Wales or Northern Ireland. 
Private/Other=PrEP users who last sourced PrEP either through online purchase, buying privately from a clinic, through a friend/re-seller, using PEP as PrEP or obtaining while travelling 
abroad 
Data completeness: STI prophylaxis: 99.6% (1,848/1,856), Gender: 99.8% (1,853/1,856), Sexual Orientation: 100% (1,856/1,856) , Ethnicity: 99.2% (1,841/1,856), Age: 99.8% 
(1,852/1,856), Residence: 99.6% (1,849/1,856), Recruitment: 99.1% (1,839/1,856), Last PrEP sourced from: 99.7% (1,851/1,856), Ever shared/ sold PrEP intended/ bought by yourself: 
99.8% (1,853/1,856), Dosing: 100% (1,856/1,856), Number of condomless anal/vaginal sex partners in past 6 months: 99.8% (1,853/1,856), Transactional sex: 99.6% (1,848/1,856), Used 
drugs just before or during sex in past 12 months (4 chemsex drugs): 98.5% (1,829/1,856), Injected drugs just before or during sex in past 12 months: 98.2% (1,823/1,856), Visited sexual 
health clinic in last year: 100% (1,856/1,856), Number of HIV tests in the last 12 months:  99.1% (1,840/1,856), Setting of last HIV test:  99.6% (1,848/1,856), Number of STI tests 
(excluding HIV) in last 12 months: 99.7% (1,846/1,856), Setting of last STI test: 99.0% (1,838/1,856), STI diagnosis in last 12 months: 99.5% (1,846/1,856), STIs diagnosed in last 12 
months: 99.8% (909/911), Satisfied with sex life: 100% (1,856/1,856) 
 
